(Monoclonal ANTIbody-targeted CARBon Nanotubes against Cancer)
is a European Commission FP7 funded research programme.
The main objective of ANTICARB is the design and development of
carbon nanotube-antibody (CNT-Ab) constructs. They are investigated
as novel platforms for cancer treatment with the purpose to act
as combinatory therapeutic/diagnostic agents.
The ANTICARB project
involves the construction and characterisation of CNT-Ab conjugates
and the determination of their biological and toxicological activity
with the ultimate aim of translation to a clinical onlcology setting.
The conjugates are designed to attain the characteristics of their
Antibodies:- clinically-used cancer therapeutic and targeting
Carbon Nanotubes:- novel nanomaterials that offer an
array of interesting features.
The ANTICARB Consortium aims to act as a multidisciplinary team
working together for the biomedical exploration of CNT-Ab constructs
with a particular focus on cancer.